Publications

2005: First RSK specific inhibitor isolated

2006 — RSK2 nuclear localization key event for breast cell transformation

2008 — YB-1 is a highly predictive biomarker for aggressive breast cancer

2008 — RSK is a major facilitator of YB-1 function in BLBC

2009 — RSK1 & 2 promising target in ER negative breast cancer

2011 — RSK is a promising target for oncogenic RAS/MAPK cancers

2011 — TNBC is functionally dependent on RSK

2012 — SiRNA silencing of RSK leads to TNBC growth inhibition and apoptosis

2013 — RSK promotes checkpoint silencing and chemo-resistance

2014 — Validation of association between YB-1 and BLBC

2014 — TNBC exquisitely sensitive to RSK inhibitors

2014 — RSK identified as 1 of 13 druggable kinases for TNBC

2015 — RSK inhibition overcomes chemo-resistance

2016 — Unlike MEK inhibition, RSK doesn't activate Akt

2016 — RSK is an untapped source of drug targets

2017 — First orally available potent and selective RSK inhibitors patented

2018 — Nuclear RSK2 essential for breast cancer formation

2022 — An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

2022 — The novel RSK2-YB-1-KLF5-KRT16/Ly6D axis provides candidate diagnostic markers and therapeutic targets for BLBC

2022 — Targeted Treatment of Triple-Negative Breast Cancer (KOL)

2023 — Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion

2025 — Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities